Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 39

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 39
---
 ​                  | ​ | ​                          | ​ | ​                  | ​ | ​                    | ​  | ​  |
| Performance Objective & Payout Modification |   | Threshold          |   | Target                     |   | Maximum            |   | Actual               |    |    |
| Relative TSR                                | ​ | 15 pts below index | ​ | Equal to index performance | ​ | 15 pts above index | ​ | 38.6 pts above index | ​  |    |
| Payout Modification                         | ​ | -25%               | ​ | 0%                         | ​ | +25%               | ​ | +25% Modification    | ​  | ​​ |

Policies and Practices Related to the Timing of Grants of Certain Equity Awards AbbVie’s policy with respect to its annual equity award for all eligible employees, including the NEOs, is to grant the award and set the grant price, which is used to calculate the number of shares covered by awards and establish the exercise price for stock options, at the compensation committee’s regularly scheduled February meeting each year. These meeting dates generally are the third Thursday of February and are scheduled two years in advance. The grant price is the average of the highest and lowest trading prices of a common share on the date of the grant (rounded up to the next even penny). The grant price for the 2024 annual grant was $175.28. The high, low and closing prices of an AbbVie common share on the grant date (February 15, 2024) were $176.74, $173.81, and $176.59 respectively. All LTI awards are subject to a minimum vesting period of 12 months. The company does notschedule its equity grantsin anticipation of the release of material, non-public information (“MNPI”) or time the release of MNPI based on equity grant dates. The following table presents information regarding option awards granted to our NEOs in the fiscal year ended December 31, 2024, during any period beginning four business days before the filing or furnishing of a periodic report or current report disclosing MNPI and ending one business day after the filing or furnishing of such report with the SEC.

| ​​​​​​​​​​​​​​​ |

46 | 2025 Proxy Statement

| ​ | ​                      |
| ​ | EXECUTIVE COMPENSATION |

| Name                  |     | Grant date |     |      Number of 
     securities 
 underlying the 
          award |     | Exercise